Veracyte Names Kevin Haas as Chief Development and Technology Officer

Core Viewpoint - Veracyte, Inc. has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer to enhance its global product development strategy in cancer diagnostics [1][3] Group 1: Leadership Appointment - Kevin Haas will join Veracyte on March 24, 2026, in a newly created role focused on overseeing end-to-end product development, including diagnostic assay development, software, and bioinformatics [1][2] - Dr. Haas has over 15 years of experience in the life sciences industry, previously serving as Chief Technology Officer at Myriad Genetics, where he led the development of precision medicine platforms [3][4] Group 2: Product Development Strategy - The expansion of Veracyte's pipeline into whole-genome minimal residual disease (MRD) and multiomics applications necessitates integrated capabilities across assays, software, AI, and next-generation informatics [2] - Dr. Haas will lead efforts to deliver high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products, aiming to accelerate innovation and support the company's global portfolio [2][3] Group 3: Company Vision and Goals - Veracyte aims to transform cancer care by providing clinicians with high-value insights for diagnosing and treating cancer, supported by a robust diagnostics platform [5][6] - The company emphasizes the importance of genomic and clinical data, bioinformatics, and AI capabilities in driving innovation and pipeline development [5][6]